A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

Also called NCT07754825

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07754825
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07754825. Randomized; double masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
LT3001 Drug:high dose
Intervention (Drug)
LT3001 Drug: low dose
Intervention (Drug)
Placebo
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07754825
Content hash
97981eb52a1ec1e83daf5a6659a9b9d1bb04a9bafec33ada8b081eec72131988